Want to see GB:IXI full AI Analyst Report?
Top Page
IXICO plc
(LSE:IXI)
Select Model
Select Model
Rating:56Neutral
Price Target:
7.50 p
▼(-3.23% Downside)
Action:Reiterated
Date:08/22/26
The score is held back primarily by weak financial performance (ongoing losses and negative operating cash flow) and bearish technicals (below major moving averages with negative MACD). These are partially offset by a relatively positive earnings-call outlook featuring strong order-book visibility, improving margins, reiterated guidance, and strengthened cash following the capital raise.
Positive Factors
Strong Revenue Growth and Order-Book Visibility
Double-digit growth and a record order book provide meaningful forward revenue visibility. The 1.75 book-to-bill ratio indicates new contract intake is exceeding recognized revenue, supporting continued expansion over the next several months.
Negative Factors
Persistent Losses and Delayed Sustainable Profitability
The company has not yet demonstrated a profitable operating model and expects continued investment-related pressure. The 2029 profitability target implies a prolonged period in which earnings may remain weak and execution risk remains material.
Read all positive and negative factors
Positive Factors
Negative Factors
Strong Revenue Growth and Order-Book Visibility
Double-digit growth and a record order book provide meaningful forward revenue visibility. The 1.75 book-to-bill ratio indicates new contract intake is exceeding recognized revenue, supporting continued expansion over the next several months.
Read all positive factors
IXICO plc (IXI) vs. iShares MSCI United Kingdom ETF (EWC)
Market Cap
£16.42M
Dividend YieldN/A
Average Volume (3M)22.43K
Price to Earnings (P/E)―
Beta (1Y)0.63
Revenue Growth13.04%
EPS Growth15.88%
CountryUK
Employees79
SectorHealthcare
Sector Strength45
IndustryBiotechnology
Share Statistics
EPS (TTM)-0.02
Shares Outstanding218,974,290
10 Day Avg. Volume26,091
30 Day Avg. Volume22,433
Financial Highlights & Ratios
PEG Ratio0.13
Price to Book (P/B)1.01
Price to Sales (P/S)1.81
P/FCF Ratio-12.69
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.01
Revenue Forecast (FY)£7.50M
IXICO plc Business Overview & Revenue Model
Company Description
IXICO plc, a London-based company established in 1995, specializes in providing data analytics services to the global biopharmaceutical industry. Operating across the UK, Europe (including Switzerland, Netherlands, Ireland), the United States, and...
How the Company Makes Money
IXICO makes money by providing outsourced clinical trial services focused on imaging and biomarker data to life sciences customers. Its core revenue is generated from contracts with pharmaceutical and biotechnology companies (and, where applicable...
IXICO plc Earnings Call Summary
Earnings Call Date:May 19, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Dec 08, 2026
Earnings Call Sentiment Positive
The call conveyed solid operational progress and strong commercial momentum: double-digit revenue growth (23% in H1), a record GBP 18.1m order book providing 95% coverage of FY26 guidance, improved gross margin (53%), a narrowed EBITDA loss (GBP 0.5m), a successful GBP 10m capital raise and a strategic Medidata partnership that supports productization and scaling. Offsetting these positives are continuing near-term losses, timing risk for TechBio-derived recurring revenue due to productization and regulatory timelines, some exposure to trial descopes/cancellations and the need to convert an increasingly promising pipeline into contracted revenue in large indications like Alzheimer’s and Parkinson’s. Overall, the momentum and balance sheet reinforcement from the capital raise materially outweigh the near-term investment-driven drawbacks, but investors should note the multi-year horizon to realize TechBio recurring revenue and the stated 2029 target for sustained profitability.Positive Updates
Strong Revenue Growth
Revenue for H1 FY26 was GBP 3.9m, a 23% increase versus H1 FY25, ahead of the company's 15% full-year growth guidance.
Negative Updates
Ongoing Net Losses and Near-Term EBITDA Impact
Despite narrowed losses, the business remained EBITDA negative (GBP 0.5m loss in H1). Management expects further short-term EBITDA impact due to continued TechBio investments and has pushed sustainable profitability target to 2029.
Read all updates
Q2-2026 Updates
Positive
Negative
Strong Revenue Growth
Revenue for H1 FY26 was GBP 3.9m, a 23% increase versus H1 FY25, ahead of the company's 15% full-year growth guidance.
Read all positive updates
Company Guidance
The company reiterated full‑year revenue guidance of GBP 7.5m (15% growth target) after a strong H1: revenues of GBP 3.9m (+23% YoY), 53% gross margin and an EBITDA loss narrowed to GBP 0.5m; management said the record order book of GBP 18.1m (up 31% since year‑end and 38% vs H1 2025) provides ~95% visibility of this year’s guidance. Over the last 12 months IXICO recognized GBP 7.2m of revenue, signed GBP 12.6m of new contracts (book‑to‑bill 1.75) and now has its largest project at 19% of order book; cash at half‑year was GBP 1.7m, augmented by GBP 9.4m net raise to GBP 10.8m at end‑April, with net assets GBP 10.7m (long‑term assets ~GBP 8m, working capital ~GBP 3.3m, lease liabilities ~GBP 0.5m). Management expects sustainable profitability and positive cash flow by 2029, will keep capex at c. GBP 300k per half (plus recent ~GBP 100k IT and ~GBP 100k refurb), aims to productize 2–3 TechBio products this year and targets FDA/software‑as‑medical‑device regulatory work on a 18–24 month horizon.IXICO plc Financial Statement Overview
Summary
Income Statement
45
Neutral
Balance Sheet
60
Neutral
Cash Flow
50
Neutral
| Breakdown | TTM | Sep 2025 | Sep 2024 | Sep 2023 | Sep 2022 | Sep 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 7.28M | 6.53M | 5.77M | 6.67M | 8.64M | 9.19M |
| Gross Profit | 3.51M | 2.91M | 2.71M | 3.27M | 4.77M | 5.53M |
| EBITDA | -2.33M | -2.02M | -1.95M | -707.00K | 1.55M | 1.73M |
| Net Income | -1.82M | -1.65M | -2.00M | -1.18M | 1.03M | 1.51M |
Balance Sheet | ||||||
| Total Assets | 12.99M | 13.84M | 11.19M | 12.99M | 14.65M | 14.26M |
| Cash, Cash Equivalents and Short-Term Investments | 1.68M | 3.54M | 1.79M | 4.03M | 5.77M | 6.68M |
| Total Debt | 559.00K | 179.00K | 314.00K | 387.00K | 516.00K | 597.00K |
| Total Liabilities | 2.27M | 2.10M | 1.72M | 1.56M | 2.16M | 2.78M |
| Stockholders Equity | 10.72M | 11.74M | 9.46M | 11.43M | 12.49M | 11.48M |
Cash Flow | ||||||
| Free Cash Flow | -2.17M | -934.00K | -2.20M | -1.66M | -815.00K | -1.54M |
| Operating Cash Flow | -2.02M | -883.00K | -1.73M | 302.00K | 1.43M | 614.00K |
| Investing Cash Flow | -1.11M | -870.00K | -377.00K | -1.86M | -2.25M | -2.15M |
| Financing Cash Flow | -202.00K | 3.50M | -134.00K | -156.00K | -114.00K | 270.00K |
IXICO plc Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
56 Neutral | £16.42M | -3.83 | -16.18% | ― | 13.04% | 15.88% | |
53 Neutral | £45.78M | -7.44 | -14.65% | 3.01% | -25.43% | -155.41% | |
53 Neutral | £2.49M | -3.09 | -89.43% | ― | 91.27% | 60.98% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
47 Neutral | £322.73M | -7.84 | -2929.47% | ― | ― | ― | |
46 Neutral | £13.01M | -3.75 | -135.35% | ― | 13.42% | 65.63% | |
38 Underperform | £15.46M | -0.29 | -451.74% | ― | 33.37% | 86.41% |
* Healthcare Sector Average
GB:IXI
IXICO plc
7.50
-4.00
-34.78%
GB:AVCT
Avacta Group plc
73.00
19.00
35.19%
GB:OBD
Oxford BioDynamics
0.12
-0.34
-74.44%
GB:PYC
Physiomics
0.53
0.05
10.53%
GB:HVO
Open Orphan Plc
6.55
-2.73
-29.42%
GB:APTA
Aptamer Group Plc
0.38
-0.63
-62.50%
IXICO plc Corporate Events
Business Operations and Strategy
IXICO grants 400,000 low-priced share options to advisors
Positive
Jul 27, 2026
IXICO plc has granted 400,000 share options to its advisors as part of a newly approved non-employee sub-plan to its existing share option scheme. The move follows shareholder approval in April 2026 and sets vesting over a two-year period, alignin...
Other
IXICO Chair Mark Warne Boosts Stake with Fresh Share Purchase
Positive
Jul 15, 2026
IXICO plc reported that Non-Executive Chair Mark Warne has increased his personal stake in the company by purchasing 50,006 ordinary shares at 7.975 pence each. Following the transaction, Warne now holds 247,341 shares, representing 0.11% of IXICO...
Business Operations and StrategyFinancial Disclosures
IXICO Maintains Upgraded Revenue Guidance Despite Huntington’s Trial Setbacks
Positive
Jul 13, 2026
IXICO plc, a global specialist in AI-driven neuroscience imaging and biomarker analytics, is embedded in the neurological disease research community through its role as an Imaging Contract Research Organisation. The company’s IXI platform pr...
Business Operations and StrategyFinancial Disclosures
IXICO lifts revenue outlook as neuroscience imaging strategy gains traction
Positive
Jul 7, 2026
IXICO plc, a specialist in AI-driven neuroscience imaging and biomarker analytics, provides services as an Imaging Contract Research Organisation to leading pharmaceutical firms, biotechs, disease consortia and non-profit groups focused on neurolo...
Business Operations and Strategy
IXICO CEO Exercises Options as Share Count Rises to Nearly 219 Million
Positive
Jun 19, 2026
IXICO plc has issued 926,686 new ordinary shares following the exercise of share options under its October 2024 Option Awards, all taken up by chief executive Bram Goorden, who funded associated taxes and costs without selling any shares. Goorden&...
Business Operations and StrategyExecutive/Board Changes
IXICO bolsters neuroimaging expertise with top advisors and new Parkinson’s collaborations
Positive
Jun 8, 2026
IXICO plc, a neuroscience-focused imaging CRO, has expanded its Scientific Advisory Board with leading Alzheimer’s and Parkinson’s disease experts Professor Jeffrey Cummings, Professor Charles DeCarli and Professor Stéphane Leh...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.